Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eluxadoline - AbbVie

Next Previous
Drug Profile

Eluxadoline - AbbVie

Alternative Names: JNJ-27018966; Mu Delta; TRUBERZI; VIBERZI

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer AbbVie
  • Class Amides; Benzoic acids; Imidazoles; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome

Most Recent Events

  • 02 Feb 2026 Eluxadoline is still in phase-III trials in Irritable bowel syndrome (In adolescents, In children) in USA (PO) (NCT04880876)
  • 13 Aug 2021 Phase-III clinical trials in Irritable bowel syndrome (In adolescents, In children) in USA (PO) (NCT04880876)
  • 18 May 2021 AbbVie plans a phase III long term safety trial for Irritable bowel syndrome diarrhoea-predominant (In adolescents, In children) (PO) in May 2021 (NCT04880876)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top